HTB

Lipodystrophy and metabolic complications

Switch to abacavir improves lipoatrophy

Potential use of niacin to reduce intra-abdominal fat

Further benefits shown with New-Fill for facial atrophy

Lipodystrophy associated with lower CD4+ T cell counts

Leptin reverses lipodystrophy in diabetic patients

Meeting calls for NHS funding and training to provide repair treatment for people with facial lipoatrophy

Managing the metabolic side effects of antiretroviral therapy

Intensive diet and exercise regimen may help fight lipodystrophy

Endocrine disorders complicate ARV treatment

Fat distribution is strongly tied to metabolic disturbances in HIV lipodystrophy

Eating more often can reduce cholesterol levels

Further reports of benefits of polylactic acid for facial lipoatrophy

Lipodystrophy in HAART-treated patients may have multifactorial aetiology

Dihydrotestosterone for HAART-associated breast enlargement in men

Osteopenia seen in testosterone-deficient women with AIDS wasting

Dietary factors, metabolic abnormalities and fat redistribution

Lipodystrophy and metabolic disturbances

Does efavirenz cause breast enlargement?

HCV coinfection may have role in changes in body composition in HIV patients

Treatment of hyperlipidemia in HIV-positive patients

Risk of lipodystrophy in HIV-positive treated with PIs: a prospective cohort study

Studies underway on metabolic side effects of antiretrovirals

Inflammatory stimulus may contribute to HIV lipodystrophy

Reports on lipodystrophy and metabolic complications

Lipodystrophy: the current state of play

Metabolic effects – bone density and avascular necrosis

Lipoatrophy and facial wasting

Metabolic and lipodystropy issues: confusion continues to reign

Switching studies: Can viral load be maintained and metabolic or fat redistribution significantly improved?

Post navigation